Skip to main content
Clinical Trials/JPRN-UMIN000043235
JPRN-UMIN000043235
Recruiting
N/A

An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)". - Biomarker study in cell free DNA of Gio-Tag Japan.

HANSHIN Oncology Group0 sites93 target enrollmentFebruary 3, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
non-small cell lung cancer(EGFR mutation positive)
Sponsor
HANSHIN Oncology Group
Enrollment
93
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 3, 2021
End Date
July 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
HANSHIN Oncology Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials